Compass Therapeutics Inc (CMPX) Stock Price, Quote & News

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8099

Website: www.compasstherapeutics.com

Address:

80 Guest Street, Suite 601, Boston, United States

wanderlust222 Aug. 24 at 2:13 PM

$CMPX queue annoying guy whining

0 · Reply

TBROS1898 Aug. 24 at 1:36 PM

$CMPX wrong way damnt

0 · Reply

Frank_Linde Aug. 21 at 9:44 PM

$CMPX Time to ramp up volume next week 🙏

0 · Reply

Heliosphere Aug. 21 at 8:29 PM

$CMPX https://investors.compasstherapeutics.com/static-files/f17bdebf-7c78-41c3-b486-e3abf62ecc51

0 · Reply

Heliosphere Aug. 21 at 8:25 PM

$CMPX 3. New IST added — nab-paclitaxel formulation The 1L IST pipeline now reads “Tovecimig + CTX-8371 + nab-paclitaxel + gemcitabine” — the July deck said just “paclitaxel.” The switch to nab-paclitaxel is clinically meaningful: better tumor penetration, different toxicity profile, no Cremophor hypersensitivity, and increasingly preferred in pancreatic and biliary cancers. This is a legitimate scientific upgrade to the combination regimen.

0 · Reply

Heliosphere Aug. 21 at 8:24 PM

$CMPX 2. PFS2 HR changed — important discrepancy now resolved Slide 14 now shows the prespecified PFS2 crossover analysis as HR=0.54, p=0.065 — whereas the July 1 deck showed HR=0.36. This is a significant change. HR=0.54 is materially less impressive than HR=0.36. This confirms the June 2026 data cutoff maturation weakened the crossover PFS2 signal — but the OS benefit in crossover patients (HR=0.54, p=0.04) remains statistically significant and unchanged.

0 · Reply

Heliosphere Aug. 21 at 8:22 PM

$CMPX There’s a new August 2026 corporate presentation on the Compass IR site. 1. New data cutoff — June 2026 replaces April 2026 Every COMPANION-002 slide now carries a “Data cutoff from COMPANION-002 as of June 2026” notation — two months more mature than the July 1 deck. This is the dataset being taken to FDA. The ORR, PFS, and OS numbers are unchanged numerically, confirming the dataset has stabilized. But the DoR data and any maturing responses will be in the package without being disclosed publicly yet — that’s reserved for ESMO October.

0 · Reply

TooMuchFinesse Aug. 21 at 2:10 PM

$CMPX we will be rewarded nicely Helio! We’ve done the work. We’ve went through the rabbit holes. This is one of those stocks they’ll see trending on a random winter day and wonder ..”how did I miss this one?” Because Biotech data is the most annoying Dd to do and ppl often skip over it. We did not. Easy rewards in biotech stocks when you dig deep enough.

1 · Reply

Heliosphere Aug. 21 at 12:06 PM

$CMPX latest compiled analyst data show: * Stifel — Buy, $6, maintained Aug. 14. * Canaccord Genuity — Buy, $7, reiterated Aug. 7. * Piper Sandler — Buy, target raised $4 → $6, Aug. 7. * Leerink Partners — Buy, target raised $4 → $7, Aug. 7. * William Blair — Buy, reiterated Aug. 7, without a published target. * Current compiled consensus: Strong Buy, average target approximately $8.92 across 15 analysts. The Leerink $4 → $7

1 · Reply

Evaluwait Aug. 20 at 6:13 PM

$CMPX Interesting action today. The trajectory here becomes much more obvious in the next few weeks after FDA meeting on intent to file.

0 · Reply

Compass Therapeutics price target raised to $7 from $4 at Leerink

Aug 6, 2026, 7:30 AM EDT - 18 days ago

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Aug 6, 2026, 7:30 AM EDT - 18 days ago

Compass Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 7:30 AM EDT - 18 days ago

Compass Therapeutics Quarterly report: Q2 2026

Jul 17, 2026, 10:42 AM EDT - 5 weeks ago

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Jun 9, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 8:45 AM EDT - 2 months ago

Compass Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 7:30 AM EDT - 3 months ago

Compass Therapeutics to Participate in Upcoming June Investor Events

May 21, 2026, 5:00 PM EDT - 3 months ago

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

May 20, 2026, 11:30 AM EDT - 3 months ago

Compass Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 19, 2026, 1:30 PM EDT - 3 months ago

Compass Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 7:30 AM EDT - 3 months ago

Compass Therapeutics to Participate in Upcoming May Investor Events

2026-05-05T12:13:40.000Z - 3 months ago

Compass Therapeutics reports Q1 EPS (10c), consensus (10c)

May 5, 2026, 7:30 AM EDT - 3 months ago

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

May 5, 2026, 7:30 AM EDT - 3 months ago

Compass Therapeutics Earnings release: Q1 2026

May 5, 2026, 7:30 AM EDT - 3 months ago

Compass Therapeutics Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Compass Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Compass Therapeutics Proxy statement: Proxy filing

2026-04-28T11:13:42.000Z - 4 months ago

Compass Therapeutics price target lowered to $7 from $13 at Canaccord

2026-04-28T10:32:11.000Z - 4 months ago

Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James

2026-04-27T19:20:47.000Z - 4 months ago

Compass Therapeutics price target lowered to $6 from $12 at Stifel

2026-04-27T18:05:41.000Z - 4 months ago

Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies

2026-04-27T17:05:11.000Z - 4 months ago

Leerink says Compass data supports path forward for tovecimig in 2L BTC

Apr 27, 2026, 1:00 PM EDT - 4 months ago

Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-04-27T15:55:10.000Z - 4 months ago

H.C. Wainwright keeps Buy rating on Compass Therapeutics after data

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Compass Therapeutics Transcript: Study update

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Compass Therapeutics Press release: Study update

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Compass Therapeutics Slides: Study update

2026-04-27T11:51:55.000Z - 4 months ago

Compass Therapeutics reports additional COMPANION-002 study results

Apr 27, 2026, 7:30 AM EDT - 4 months ago

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Apr 24, 2026, 4:00 PM EDT - 4 months ago

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

2026-03-05T12:38:02.000Z - 6 months ago

Compass Therapeutics reports Q4 EPS (9c), consensus (9c)

Mar 5, 2026, 7:30 AM EST - 6 months ago

Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

Mar 5, 2026, 7:30 AM EST - 6 months ago

Compass Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 7:30 AM EST - 6 months ago

Compass Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:30 AM EST - 6 months ago

Compass Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 6 months ago

Compass Therapeutics Slides: Corporate presentation

2026-02-13T14:16:09.000Z - 6 months ago

Craig-Hallum bullish on Compass Therapeutics, initiates with a Buy

2026-02-13T13:15:26.000Z - 6 months ago

Compass Therapeutics initiated with a Buy at Craig-Hallum

2026-02-04T11:42:54.000Z - 7 months ago

Compass Therapeutics price target raised to $13 from $10 at Canaccord

Jan 14, 2026, 10:30 AM EST - 7 months ago

Compass Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:00 AM EST - 8 months ago

Compass Therapeutics Slides: Corporate presentation

2026-01-06T13:36:59.000Z - 8 months ago

Compass Therapeutics provides corporate update

Jan 6, 2026, 8:00 AM EST - 8 months ago

Compass Therapeutics Provides Corporate Update

Jan 5, 2026, 4:30 PM EST - 8 months ago

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-01-05T13:38:26.000Z - 8 months ago

Compass Therapeutics appoints Arjun Prasad as CCO, Cynthia Sirard as CMO

Jan 5, 2026, 8:00 AM EST - 8 months ago

Compass Therapeutics Announces Key Leadership Appointments

2026-01-05T11:01:21.000Z - 8 months ago

Compass Therapeutics initiated with an Outperform at William Blair

Dec 30, 2025, 7:00 AM EST - 8 months ago

Compass Therapeutics Registration statement: Registration Filing

Dec 17, 2025, 7:30 AM EST - 8 months ago

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

Dec 4, 2025, 10:00 AM EST - 9 months ago

Compass Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:00 AM EST - 9 months ago

Compass Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 9 months ago

Compass Therapeutics to Participate in Upcoming December Investor Events

Nov 20, 2025, 7:30 AM EST - 9 months ago

Compass Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:00 PM EST - 10 months ago

Compass Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 3:30 PM EST - 10 months ago

Compass Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 9, 2025, 6:00 PM EST - 10 months ago

Compass Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 4:00 PM EST - 10 months ago

Compass Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 10 months ago

Compass Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:30 AM EST - 10 months ago

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 9:00 AM EST - 10 months ago

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 3, 2025, 8:00 AM EST - 10 months ago

Compass Therapeutics to Participate in Upcoming November Investor Events

Sep 9, 2025, 5:35 PM EDT - 1 year ago

Compass Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 11:00 AM EDT - 1 year ago

Compass Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 2:10 PM EDT - 1 year ago

Compass Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in Upcoming September Investor Events

Aug 12, 2025, 10:28 PM EDT - 1 year ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Compass Therapeutics Announces Proposed Public Offering

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Compass Therapeutics Slides: Corporate Presentation

Aug 8, 2025, 4:01 PM EDT - 1 year ago

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Jun 5, 2025, 11:05 AM EDT - 1 year ago

Compass Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Compass Therapeutics Slides: Investor Presentation

May 28, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 20, 2025, 11:30 AM EDT - 1 year ago

Compass Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 8, 2025, 1:30 PM EDT - 1 year ago

Compass Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Quarterly report: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Proxy statement: Proxy Filing

$Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting$

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Apr 8, 2025, 3:00 PM EDT - 1 year ago

Compass Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Transcript: Study Update

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Slides: Study Update

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Earnings release: Q4 2024

Feb 6, 2025, 9:00 AM EST - 1 year ago

Compass Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Dec 10, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Dec 4, 2024, 9:50 AM EST - 1 year ago

Compass Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 9:00 AM EST - 1 year ago

Compass Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Compass Therapeutics to Participate in Upcoming Investor Events

Nov 12, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compass Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compass Therapeutics Earnings release: Q3 2024

Nov 8, 2024, 10:05 AM EST - 1 year ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 10:31 AM EDT - 2 years ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Sep 9, 2024, 11:00 AM EDT - 2 years ago

Compass Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 30, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Registration statement: Registration Filing

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Compass Therapeutics Slides: Corporate Presentation

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

May 29, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Proxy statement: Proxy Filing

May 28, 2024, 4:10 PM EDT - 2 years ago

Compass Therapeutics Announces CEO Transition

May 23, 2024, 5:05 PM EDT - 2 years ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

May 14, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

May 13, 2024, 7:00 AM EDT - 2 years ago

Compass Therapeutics Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Compass Therapeutics Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Apr 9, 2024, 12:00 PM EDT - 2 years ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Annual report: Q4 2023

Feb 29, 2024, 8:00 AM EST - 2 years ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Nov 9, 2023, 7:30 AM EST - 3 years ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 3 years ago

Compass Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 3 years ago

Compass Therapeutics Earnings release: Q3 2023

Aug 3, 2023, 8:00 AM EDT - 3 years ago

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

wanderlust222 Aug. 24 at 2:13 PM

$CMPX queue annoying guy whining

0 · Reply

TBROS1898 Aug. 24 at 1:36 PM

$CMPX wrong way damnt

0 · Reply

Frank_Linde Aug. 21 at 9:44 PM

$CMPX Time to ramp up volume next week 🙏

0 · Reply

Heliosphere Aug. 21 at 8:29 PM

$CMPX https://investors.compasstherapeutics.com/static-files/f17bdebf-7c78-41c3-b486-e3abf62ecc51

0 · Reply

Heliosphere Aug. 21 at 8:25 PM

0 · Reply

Heliosphere Aug. 21 at 8:24 PM

0 · Reply

Heliosphere Aug. 21 at 8:22 PM

0 · Reply

TooMuchFinesse Aug. 21 at 2:10 PM

1 · Reply

Heliosphere Aug. 21 at 12:06 PM

1 · Reply

Evaluwait Aug. 20 at 6:13 PM

$CMPX Interesting action today. The trajectory here becomes much more obvious in the next few weeks after FDA meeting on intent to file.

0 · Reply

TBROS1898 Aug. 20 at 2:39 PM

$CMPX weak ass hands yall

0 · Reply

TBROS1898 Aug. 20 at 2:38 PM

$CMPX figures 🙄

0 · Reply

Brandonswest Aug. 20 at 5:12 AM

$CMPX those are the 2 sponsored by Washington U. There is also a new Phase 2 trial just starting to spin up sponsored by $CMPX : Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms http://ClinicalTrials.gov ID NCT07684170

0 · Reply

Heliosphere Aug. 20 at 1:58 AM

$CMPX Compass’s latest 10-Q confirms two additional investigator-sponsored trials have now been initiated: Second-line metastatic CRC: tovecimig + FOLFIRI, Phase 2, Washington University, NCT07662031. Recurrent glioblastoma: tovecimig ± CTX-471, Phase 1/2, Washington University, NCT07392957.

0 · Reply

Heliosphere Aug. 20 at 1:57 AM

$CMPX A 2026 review in Frontiers in Oncology, “Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms,” includes CTX-009/tovecimig in its discussion of the evolving BTC treatment landscape. https://pmc.ncbi.nlm.nih.gov/articles/PMC12932168/

0 · Reply

Heliosphere Aug. 20 at 1:54 AM

$CMPX ASCO’s Daily News has a dedicated article titled “Tovecimig (CTX-009), a Bispecific Antibody Targeting DLL4 and VEGF-A: Perspectives from the Field.” https://dailynews.ascopubs.org/do/tovecimig-ctx-009-bispecific-antibody-targeting-dll4-and-vegf-a-perspectives-field?utm_source=chatgpt.com

0 · Reply

NFA_DYOR Aug. 19 at 9:46 PM

$CMPX

0 · Reply

KingFobby Aug. 19 at 8:02 PM

$CMPX

0 · Reply

GangsterX Aug. 19 at 6:52 PM

$CMPX sold 75%.. hold small position now... I think FDA will allow them to submit NDA but there is a risk... better bet small

2 · Reply

Evaluwait Aug. 19 at 6:45 PM

$CMPX Retail folks may not be getting the fact 3 investigator sponsored studies for Avastin displacement is a big big deal. Even an onc surgeon friend initially failed to see what that means. As I have told friends, this has the best shot or one of the best shots of stocks I own or follow at being a 4x to 20x play in 5 or 6 years. But there is a 20 percent shot at negative to zero returns too. Too many retail folks, including those I know, lack the ability to just sit, watch and wait. I learned that lesson the hard way.

1 · Reply

TBROS1898 Aug. 19 at 6:33 PM

$CMPX papa got them new shoes coming 😀

0 · Reply

Evaluwait Aug. 19 at 5:04 PM

$CMPX why would the FDA not grant approval to a drug with a strong signal that patients and KOLs want??

1 · Reply

Market Cap	432.21M
Revenue (ttm)	0.00
Net Income (ttm)	-66.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	974,000
Avg Vol	3,145,964
Day's Range	N/A - N/A
Shares Out	180.09M
Stochastic %K	66%
Beta	0.92
Analysts	Strong Sell
Price Target	$8.92